Retatrutide: Reference Overview and Reconstitution Notes

Retatrutide is a lab-made (synthetic) peptide that switches on three different receptors in the body at once. Those receptors are GIP, GLP-1, and glucagon. It is being studied in the areas of metabolism and body-weight regulation. It has not been approved by the FDA.

Retatrutide

What it is

Key point: Retatrutide is an investigational (not yet approved) triple agonist. A triple agonist is a compound that activates three receptors at once: GIP, GLP-1, and glucagon. It is not approved by the FDA.

Retatrutide is also known by the lab code LY3437943. It is a synthetic peptide, meaning a small protein-like molecule built in a lab. It is made of 39 amino acids (the tiny building blocks that link together to form proteins). It was developed by Eli Lilly.

Think of it like a key that fits three different locks at the same time. One molecule activates three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. Each of these receptors plays a role in how the body handles energy and blood sugar.

Research context and categorization

Retatrutide falls into the metabolic and weight-regulation category. Researchers discuss it alongside GLP-1 and dual GIP/GLP-1 receptor agonists. These are compounds that work on similar signaling pathways in the body. Retatrutide extends that group by adding a third target: the glucagon receptor.

Investigational Areas

In research and clinical trial settings, retatrutide has been studied for effects on body weight and blood-sugar levels. Eli Lilly has described trials looking at it in the context of:

• Obesity and overweight with a weight-related condition
• Type 2 diabetes
• Knee osteoarthritis
• Obstructive sleep apnea
• Chronic low back pain
• Cardiovascular and kidney outcomes
• Metabolic dysfunction-associated steatotic liver disease

Because retatrutide is not approved by the FDA or other major regulators, all of these uses are investigational. That means they are still being studied and have not been confirmed or approved. Any numbers reported in trials should be read as research findings, not proven benefits.

Status

• Regulatory status: Research-only and investigational. As of mid-2026, retatrutide is not FDA-approved for any use. It is still in clinical development (Phase 3 trials, which are large human studies done before a drug can seek approval). It is not available as an approved medicine.
• Sport status: Prohibited under the WADA Prohibited List (the global anti-doping rulebook). The clearest basis is category S0 (non-approved substances), which bans any substance not yet approved by a government health authority for human use. It is also discussed under the peptide hormones and growth factors class (S2) and, in some analyses, hormone and metabolic modulators (S4). Athletes should treat it as prohibited.

Reconstitution notes (general)

Retatrutide is supplied as a lyophilized (freeze-dried) powder. Before lab use, it is mixed with liquid to turn it into a solution. This step is called reconstitution. The concentration of the final solution equals the milligrams of powder in the vial divided by the milliliters of bacteriostatic water added.

For example, a 10 mg vial mixed with 2 mL of bacteriostatic water gives a solution of 5 mg/mL. You can use the peptide calculator to work out concentrations easily.

Dilution and handling notes (compound-specific)

Because retatrutide comes as a freeze-dried powder, it must be reconstituted before use. It does not ship as a ready-to-use liquid. Common water-to-vial ratios are chosen so that a small, easy-to-measure volume lines up with round numbers on an insulin syringe.

For instance, common mixes include about 2 mL of bacteriostatic water into a 10 mg vial (giving 5 mg/mL), or about 2 mL into a 20 mg vial (giving 10 mg/mL). Larger vials (for example, 40 mg) sometimes take 2 to 3 mL.

Bacteriostatic water contains benzyl alcohol as a preservative. That preservative slows bacterial growth. This makes it generally preferred over plain sterile water because it allows repeated draws from the same vial across the refrigerated storage window.

Handling Best Practices

Standard reconstitution handling involves specific steps to protect the compound:

1. Run the water slowly down the inner wall of the vial rather than squirting it directly onto the powder.
2. Roll or swirl the vial gently between your fingers instead of shaking it. Forcing the liquid in too fast and shaking the vial can create foam and may stress or damage the peptide.
3. Be patient with dissolution. Like other long-acting, fatty-acid-modified peptides in this class, retatrutide may take a short time (often a couple of minutes of gentle rolling) to fully dissolve rather than clearing right away. A dense, compact freeze-dried cake can hydrate slowly and may look clumped or gel-like at first. This is normal.

A properly mixed vial should be clear and colorless with no visible particles. Cloudiness, a color change, or visible floating bits point to a problem such as clumping, breakdown, a temperature or pH (acidity level) issue, or contamination. The right response is to discard that vial rather than try to filter or reheat it.

Retatrutide is also light-sensitive in both powder and solution form. Keep vials shielded from direct light at all times.

Handling and storage

To keep the material stable, follow these standard storage guidelines:

• Store reconstituted material in the refrigerator at 2 to 8 degrees Celsius and keep it out of light.
• Wipe the rubber stopper with alcohol before each puncture, and label the vial with the date you mixed it.
• Follow the general roughly 4-week refrigerated window commonly cited for reconstituted peptide solutions. Reports for retatrutide often note about 28 to 30 days when stored properly.
• Discard anything that has turned cloudy or discolored, or that has visible particles floating in it.

Related reading

• SS-31 (Elamipretide)
• Survodutide
• VK2735
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

What receptors does retatrutide target?

Retatrutide is a triple agonist that simultaneously activates the GIP, GLP-1, and glucagon receptors, distinguishing it from dual GIP/GLP-1 agonists in the same metabolic research category.

Is retatrutide FDA-approved?

No. As of mid-2026, retatrutide remains investigational and is in Phase 3 clinical trials. It has not been approved by the FDA or other major regulatory agencies for any indication.

How do you reconstitute a lyophilized retatrutide vial for lab use?

Add bacteriostatic water to the lyophilized powder; concentration (mg/mL) equals peptide mass (mg) divided by solvent volume (mL) added. A peptide calculator can confirm the figures before use.

More in our bacteriostatic water and diluents collection.

What the research community gets wrong about retatrutide

• They think the word "triple agonist" changes how you mix it. The three receptor targets (GIP, GLP-1, and glucagon) describe what the molecule was studied to do in the body. They tell you nothing about work at the bench. On the bench you reconstitute it the same careful way as other freeze-dried peptides in this class.
• They treat it as interchangeable with tirzepatide. Tirzepatide acts on two receptors. Retatrutide is a different 39 amino acid molecule that adds a third target. They are not the same compound, so labels, records, and calculations should never be copied from one to the other.
• They assume a slow or gel-like cake means the vial went bad. Long-acting, fatty-acid-modified peptides like this one can hydrate slowly and may look clumped at first. A couple of minutes of gentle rolling is normal. Cloudiness or floating bits after full dissolution is the real warning sign.
• They shake the vial to speed things up. Shaking makes foam and adds mechanical stress that can damage the peptide. Swirl gently instead, and be patient.
• They read clinical trial weight or blood-sugar numbers as proven results. Retatrutide is investigational and not FDA-approved. Reported figures are research findings from studies, not confirmed outcomes, and they have nothing to do with bench handling.

From our bench: If you reconstitute retatrutide, log how long a fully compact cake takes to clear with gentle rolling, and note whether the solution stays clear and colorless across your refrigerated storage window. Record the vial size, the water volume you added, and the storage temperature alongside your observation so the timing means something. Share your real notes with us. We will not publish invented numbers, only what someone actually measured at the bench.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 (PubMed)
5. Retatrutide - compound record, PubChem (NIH National Library of Medicine)